At the news
? NEUTRALIMPACT 5/10 8-K filed Mar 5, 2026 at 08:02 ET
Reviva Pharmaceuticals Holdings is implementing a 1-for-20 reverse stock split effective March 9, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement after receiving a delisting notice. The reverse split aims to increase the stock price but may reduce liquidity and does not address underlying business fundamentals.
- Company is executing a 1-for-20 reverse stock split effective March 9, 2026
- Reverse split is intended to regain compliance with Nasdaq's $1.00 minimum bid price requirement
- Company received Nasdaq delisting notice on May 13, 2025 for failing to maintain $1.00 minimum bid price
- Nasdaq granted an exception period through March 27, 2026 to demonstrate compliance
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access